 |
Top 10 Blood Test and Liquid Biopsy startups in USA
Updated: May 09, 2024 |
1
Funding: $2B
The mission of Grail is to enable the early detection of cancer in asymptomatic individuals through a blood screen – with the goal of massively decreasing global cancer mortality by detection at a curable stage. Grail will leverage the power of Illumina next-generation sequencing technology, the best talent in the field and the passion of its leadership to deliver on that promise.
The mission of Grail is to enable the early detection of cancer in asymptomatic individuals through a blood screen – with the goal of massively decreasing global cancer mortality by detection at a curable stage. Grail will leverage the power of Illumina next-generation sequencing technology, the best talent in the field and the passion of its leadership to deliver on that promise.
2
Funding: $1.9B
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
3
Funding: $1.4B
Our mission is to make actionable information accessible to everyone at the time it matters. By making actionable information accessible to everyone in the world at the time it matters most, we are working to facilitate the early detection and prevention of disease, and empower people everywhere to live their best possible lives.
Our mission is to make actionable information accessible to everyone at the time it matters. By making actionable information accessible to everyone in the world at the time it matters most, we are working to facilitate the early detection and prevention of disease, and empower people everywhere to live their best possible lives.
4
Funding: $1.4B
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome. It employs Artificial Intelligence to detect colorectal cancer.
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome. It employs Artificial Intelligence to detect colorectal cancer.
5
Funding: $368.4M
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
6
Funding: $340.5M
Human Longevity is the genomics-based, technology-driven company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine.
Human Longevity is the genomics-based, technology-driven company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine.
7
Funding: $325M
EverlyWell is a digital health platform that provides at-home health tests and lab results.
EverlyWell is a digital health platform that provides at-home health tests and lab results.
8
Funding: $308.6M
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts utilizing T2MR target sepsis, hemostasis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics.
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts utilizing T2MR target sepsis, hemostasis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics.
9
Funding: $254M
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.
10
Funding: $219.5M
Epic Sciences is a diagnostics company improving cancer management by providing real-time biopsy material to guide personalized medicine.
Epic Sciences is a diagnostics company improving cancer management by providing real-time biopsy material to guide personalized medicine.
Ad
Advertise your startup
11
Funding: $154.8M
Genalyte is guided by the vision of taking a single drop of blood, performing panels of tests and returning accurate and reproducible results within a few minutes.
Genalyte is guided by the vision of taking a single drop of blood, performing panels of tests and returning accurate and reproducible results within a few minutes.
12
Funding: $150.1M
Athelas develops an in-home blood diagnostic device designed to monitor the immune system from a drop of blood.
Athelas develops an in-home blood diagnostic device designed to monitor the immune system from a drop of blood.
13
Funding: $135.6M
Tasso is revolutionizing diagnostics by creating technologies for blood sample collection that place the user at the center of process. Our wearable blood collection system, the HemoLinkTM, is being developed to improve the user experience as well as enable both healthcare consumers and providers with convenient access to reliable laboratory test results.
Tasso is revolutionizing diagnostics by creating technologies for blood sample collection that place the user at the center of process. Our wearable blood collection system, the HemoLinkTM, is being developed to improve the user experience as well as enable both healthcare consumers and providers with convenient access to reliable laboratory test results.
14
Funding: $108M
Adela creates develops technologies centered around detecting high-risk conditions like cancer through routine blood tests.
Adela creates develops technologies centered around detecting high-risk conditions like cancer through routine blood tests.
15
Funding: $98.2M
We are a privately held medical technology company focused on developing innovative blood collection devices used in research and clinical testing. Our mission is to eliminate the barriers to successful blood sample collection and testing for health care professionals and consumers with simple, safe, mobile, and nearly painless technologies.
We are a privately held medical technology company focused on developing innovative blood collection devices used in research and clinical testing. Our mission is to eliminate the barriers to successful blood sample collection and testing for health care professionals and consumers with simple, safe, mobile, and nearly painless technologies.
16
Funding: $84M
Q Bio operates as a platform that provides a physical health picture of the users.
Q Bio operates as a platform that provides a physical health picture of the users.
17
Funding: $73M
OncoCyte focused on cancers with large patient populations and significant unmet need. The company is developing three genetic tests – blood tests for breast cancer and lung cancer, and a urine-based test for bladder cancer.
OncoCyte focused on cancers with large patient populations and significant unmet need. The company is developing three genetic tests – blood tests for breast cancer and lung cancer, and a urine-based test for bladder cancer.
18
Funding: $71.2M
Velano Vascular aims to improve the hospital experience for patients and providers by reducing the pain, anxiety, and inefficiencies of blood draws.
Velano Vascular aims to improve the hospital experience for patients and providers by reducing the pain, anxiety, and inefficiencies of blood draws.
20
Funding: $35.4M
Techcyte creates AI-powered digital diagnostic tests to assist labs and clinics with a more efficient diagnostic process.
Techcyte creates AI-powered digital diagnostic tests to assist labs and clinics with a more efficient diagnostic process.
21
Funding: $18.2M
InsideTracker is a personal nutrition model by Segterra. Sophisticated, science-based blood analytics, tailored just for you. Get your personalized nutrition and lifestyle recommendations now. A simple blood test and survey will enable us to derive your unique optimal zones and tailor your recommendations to your background, lifestyle and food preferences.
InsideTracker is a personal nutrition model by Segterra. Sophisticated, science-based blood analytics, tailored just for you. Get your personalized nutrition and lifestyle recommendations now. A simple blood test and survey will enable us to derive your unique optimal zones and tailor your recommendations to your background, lifestyle and food preferences.
22
Funding: $16.8M
Banyan Biomarkers is developing the first blood test to accurately and quickly diagnose traumatic brain injury (TBI)
Banyan Biomarkers is developing the first blood test to accurately and quickly diagnose traumatic brain injury (TBI)
23
Funding: $15M
WellnessFX is a breakthrough web-based service that empowers individuals to understand and improve their health in a personalized and engaging way. By combining direct-to-consumer access to advanced blood tests, phone consultations with progressive health practitioners, and intuitive online data tracking, our customers are able to identify and reverse potential health risks long before symptoms appear.
WellnessFX is a breakthrough web-based service that empowers individuals to understand and improve their health in a personalized and engaging way. By combining direct-to-consumer access to advanced blood tests, phone consultations with progressive health practitioners, and intuitive online data tracking, our customers are able to identify and reverse potential health risks long before symptoms appear.
25
Funding: $2.4M
Delee is a medical device company that aims to revolutionize how cancer is diagnosed and managed. That is why we developed CytoCatch, a patent pending technology that enables the performance of a CTC blood-based assay that has the potential of being used for early cancer detection and monitoring of the applied treatments’ effectiveness.
Delee is a medical device company that aims to revolutionize how cancer is diagnosed and managed. That is why we developed CytoCatch, a patent pending technology that enables the performance of a CTC blood-based assay that has the potential of being used for early cancer detection and monitoring of the applied treatments’ effectiveness.
27
Funding: $619.9K
Tymora Analytical Operations discovered a way to detect and monitor breast cancer using a simple blood test and bladder cancer using a urine test.
Tymora Analytical Operations discovered a way to detect and monitor breast cancer using a simple blood test and bladder cancer using a urine test.
28
Funding: $750K
Spot On Sciences develops and markets innovative devices that revolutionize collection and storage of biological fluids for medical research and testing. Based in Austin, TX, initial products, HemaForm and HemaSpot, enable remote collection of blood samples offering solutions for multiple markets including clinical trials, biobanking, home-based wellness testing, military field medicine and population studies.
Spot On Sciences develops and markets innovative devices that revolutionize collection and storage of biological fluids for medical research and testing. Based in Austin, TX, initial products, HemaForm and HemaSpot, enable remote collection of blood samples offering solutions for multiple markets including clinical trials, biobanking, home-based wellness testing, military field medicine and population studies.